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Data on a chemical’s mechanisms of action 
can be critical to decisions in human health 
risk assessment, especially regarding poten-
tial differences in sensitivity to adverse effects 
across and within species. U.S. Environmental 
Protection Agency (EPA) guidelines for car-
cinogen risk assessment (U.S. EPA 2005) par-
ticularly emphasize the use of mechanistic 
data to inform the evaluation of the mode of 
action (MOA) of a chemical. These guidelines 
define MOA as “a sequence of key events 
and processes, starting with interaction of an 
agent with a cell, proceeding through opera-
tional and anatomical changes and result-
ing in cancer formation.” A “key event” is an 
empirically observable precursor step that is 
itself a necessary element of the MOA or is a 
biologically based marker for such an element. 
Mode is distinguished from mechanism, with 
the latter implying the complete series of 
events that lead from exposure to disease. It 
is recognized that the precise carcino  genic 
mechanism(s) is unknown for essentially all 
chemicals, and the MOA concept attempts 
to address this knowledge deficit by focusing 
on key steps required (i.e., necessary) for the 
carcinogenic process.
One of the most challenging deter-
minations in evaluating mechanistic data is 
whether an identified MOA is the cause of 
cancer (or another adverse health outcome). 
As recently reviewed (Guyton et al. 2008), 
the U.S. EPA and other MOA approaches 
have adopted the Hill (1965) considerations 
to evaluate hypothesized MOAs. However, 
the Hill considerations were not developed 
for this purpose. They were instead designed 
to assist epidemiologists in making induc-
tive inferences about the causal relationship 
of observed associations or, in the language 
of chemical carcinogenesis, as an aid in 
addressing the question, “Does a chemical 
exposure cause cancer?” Causal inference is 
often used in epidemiology because direct 
experimentation is generally not feasible; 
in contrast, MOA questions—for example, 
“How does a chemical cause cancer?”—are 
almost entirely addressed through empirical 
tests of the pertinent hypotheses in laboratory 
studies. Although some of the Hill considera-
tions (e.g., temporality and dose–response 
relationships) may be helpful in ruling out 
implausible MOAs, their general utility for 
elucidating if biological effects that may 
be similarly related to exposure (e.g., cyto-
toxicity) are actual “key events” in the causal 
pathway(s) to cancer deserves scrutiny. It is 
unclear whether they can distinguish effects 
that are merely associated with cancer (by 
virtue of a common causal connection with 
the exposure) from effects that are causally 
linked as part of an MOA for carcinogenesis. 
Moreover, even when particular effects are 
key events in a causal pathway to cancer, the 
Hill considerations cannot rule out the causal 
contribution of other effects or pathways. 
In order to address these types of inquiry, 
direct experimentation is needed, and MOA 
hypotheses should be empirically challenged 
using experimental studies, in accordance 
with the scientific method.
Another difficult aspect of mechanistic 
data evaluation is the assessment of likely 
human sensitivity to an identified laboratory 
animal MOA. The U.S. EPA (2005) guide-
lines address this issue separately during the 
hazard characterization and dose–response 
components of risk assessment, as well as in 
the identification of susceptible populations. 
This approach avoids conflating qualitative and 
quantitative issues during hazard characteriza-
tion, and thereby prevents human relevance 
from being ruled out based on differences in 
sensitivity across species. Instead, information 
suggesting quantitative differences is “flagged 
for consideration in the dose–response assess-
ment” and quantitative adjustments may also 
be made based on identified susceptibilities 
(e.g., life stage). However, a limitation of this 
approach and of MOA approaches in general 
is the tacit assumption of site concordance, 
which departs from the basic tenet of U.S. 
EPA cancer risk assessment that site concor-
dance across species is not required in hazard 
evaluation, a tenet consistent with observa-
tions of site disconcordance across countless 
rodent bioassays.
We explore these aspects of MOA 
evalua  tion in consideration of peroxisome 
proliferator–  activated receptor-α (PPAR-α) 
activation as an MOA for rodent liver tumor 
carcinogenesis. This MOA has been invoked 
to support the conclusion that environmen-
tal contaminants [e.g., the plasticizer di(2-
ethylhexyl) phthalate (DEHP)] would lack 
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activated receptor-α (PPAR-α) activation and its sequelae have been proposed to constitute a mode 
of action (MOA) for hepatocarcinogenesis by such agents as a sole causative factor. Further, based 
on a hypothesized lower sensitivity of humans to this MOA, prior reviews have concluded that 
rodent hepatocarcinogenesis by PPAR-α agonists is irrelevant to human carcinogenic risk.
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and that the MOA but not hepatocarcinogenesis is evoked by PPAR-α activation in a transgenic 
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activate PPAR-α. These findings have broad implications for how MOA hypotheses are devel-
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carcinogenic risk in humans. For instance, 
the International Agency for Research on 
Cancer (IARC) downgraded the classifica-
tion of DEHP from “possibly carcinogenic 
to humans” to “not classifiable” based on an 
expert panel’s acceptance of the hypothesis 
that DEHP induces liver tumors in rodents 
by a mechanism dependent on PPAR-α acti-
vation that is not relevant to humans (IARC 
2000). The use of evidence of the PPAR-α 
activation MOA to dismiss the human rele-
vance of effects observed in laboratory ani-
mals has been questioned (e.g., Caldwell et al. 
2008; Melnick 2001) based on the lack of 
experimental studies empirically challenging 
the MOA hypothesis.
Two recent studies have provided evidence 
that DEHP induces liver tumors in PPAR-α–
null mice (Ito et al. 2007a) and that hepato-
cyte PPAR-α activation (and its sequelae) in 
a transgenic mouse model is insuffi  cient to 
evoke hepatocarcinogenesis (Yang et al. 2007). 
These data provide motivation for the present 
reexamination of the evidential support for the 
proposed PPAR-α activation MOA hypothesis 
as a basis for assessing human health risks of 
DEHP and other environmental contaminants 
that activate PPAR-α. Although we focus on 
the human health risk assessment implica-
tions of recent data rather than comprehen-
sively reviewing the topic area, our analyses 
also encompass some prior studies reviewed 
more extensively elsewhere (Ashby et al. 
1994; Klaunig et al. 2003; Melnick 2001). 
Particularly, we examine the extent to which 
the quantitative relation  ship between the pro-
posed key events and liver tumorigenesis in 
rodents, as well as the relative human sensitiv-
ity to the hypo  thesized rodent MOA, have 
been characterized. In addition, we consider 
whether the available epidemiologic evidence 
on fibrates affords a test of the supposition 
that laboratory animal data about PPAR-α 
agonists indicate the absence of human health 
risks. We conclude with a discussion of alter-
native approaches to analyses of mechanistic 
information for chemicals of environmental 
concern that could be considered to address 
some of the challenges elaborated herein.
Is PPAR-α Activation Essential 
for DEHP Liver Carcinogenesis?
Figure 1A shows a widely cited version of 
the hypothesized MOA for hepatocarcino-
genesis induced by PPAR-α agonists, posited 
by Klaunig et al. (2003), in which three key 
causal events were proposed: activation of the 
receptor, perturbation of hepato  cellular apop-
tosis and proliferation, and selective clonal 
expansion. Klaunig et al. (2003) concluded 
that PPAR-α activation represents a key event 
in the liver tumor MOA for DEHP. The evi-
dential support included the in vitro demon-
stration of receptor activation by its monoester 
metabolite [mono-2-ethylhexyl phtha-
late (MEHP)] (Issemann and Green 1990; 
Maloney and Waxman 1999). In addition, 
peroxisome proliferation (or increased peroxi-
somal enzyme activity), an associative event in 
the MOA, was induced by tumorigenic doses 
of DEHP in the liver of mice and rats or by 
MEHP in rat hepatocytes (David et al. 1999; 
Gray et al. 1982, 1983; Hasmall et al. 1999; 
Mitchell et al. 1984, 1985; Reddy et al. 1986). 
Comparable to the results found for proto-
typical agonist [4-chloro-6-(2,3-xylidino)-
2-pyrimidyl-thio]acetic acid (Wy-14,643), 
DEHP failed to induce peroxisomal enzymes 
and peroxisome proliferation in PPAR-α–null 
mice with 24 weeks of exposure (Ward et al. 
1998). This finding supported a causal role for 
receptor activation in peroxisome proliferation, 
but a study of the subsequent development of 
tumors by DEHP in PPAR-α–null mice had 
not been conducted. However, Peters et al. 
(1997) had previously reported the absence 
of tumors in nine PPAR-α–null mice exposed 
to Wy-14,643 at 11 months, whereas each of 
Figure 1. (A) Hypothesized PPAR-α activation MOA as posited by Klaunig et al. (2003), with proposed 
“causal” events identified in green. (B) Is PPAR-α activation essential for DEHP carcinogenesis? Red 
outlines represent key events in the hypothesized PPAR-α activation MOA that were not induced by DEHP 
in PPAR-α–null mice despite the occurrence of tumors (Ito et al. 2007a; Ward et al. 1998). Proposed causal 
events are shaded pink. These key events are therefore not necessary for tumors, suggesting PPAR-α–
independent pathways for DEHP hepatocarcinogenesis. (C) Is PPAR-α activation alone sufficient for 
carcinogenesis? In the Yang et al. (2007) LAP-VP16PPAR-α transgenic model of constitutive PPAR-α activa-
tion in hepatocytes, the key events in the hypothesized PPAR-α activation MOA (green outlines), but not 
tumors, are induced at 11 months. Proposed causal events in the MOA are shaded light green. Wy-14,643 
exposure in wild-type mice induces tumors at 11 months with comparable levels of hepatocyte proliferation 
and other proposed key events. This raises questions about whether PPAR-α activation and hepatocyte 
proliferation can alone cause tumors, and suggests that the sequence of key events in the hypothesized 
MOA is not solely sufficient to evoke carcinogenesis. (D) Revisiting the PPAR-α activation MOA. DEHP is 
hepato  carcinogenic in PPAR-α–null mice in which the red-outlined key events are absent (Ito et al. 2007a; 
Ward et al. 1998), whereas, the green-outlined key events, but not tumors, are induced at 11 months in the 
LAP-VP16PPAR-α transgenic model (Yang et al. 2007). Proposed causal events are shaded light green. 
Taken together, these findings support the view that the hypothesized PPAR-α activation MOA is neither 
necessary nor sufficient for hepatocarcinogenesis as a sole causative factor.
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the six similarly exposed wild-type mice had 
multiple hepatocellular neoplasms. Based on 
this 11-month tumor bioassay of Wy-14,643 
(Peters et al. 1997) and the short-term DEHP 
study (Ward et al. 1998) in PPAR-α–null 
mice, it was assumed that “a long-term study 
of DEHP using PPAR-α–null mice would 
provide the same results” (Klaunig et al. 2003). 
This assumption in turn supported the con-
clusion that “all the effects observed are due 
only to the activation of this receptor and the 
downstream events resulting from this activa-
tion and that no other modes of action are 
operant” (Klaunig et al. 2003).
Recent studies have experimentally chal-
lenged both the assumption of a lack of carci-
nogenicity in a long-term DEHP bioassay in 
PPAR-α–null mice and the hypothesis that 
PPAR-α activation is the sole operant MOA 
for hepatocarcinogenesis. In a 2-year bio  assay, 
Ito et al. (2007a) found that DEHP (100 or 
500 ppm) induces liver tumors in PPAR-α–
null mice and they also reported a significant 
trend for the observed increase in total liver 
tumors with DEHP in PPAR-α–null male 
mice with Sv129 genetic background gener-
ated as described in Lee et al. (1995). For the 
present report, we performed additional statis-
tical analyses to compare the Ito et al. (2007a) 
results with those of a prior DEHP bio  assay in 
B6C3F1 wild-type mice (David et al. 1999). 
A pairwise analysis showed that DEHP (500 
ppm) significantly increased adenomas in 
PPAR-α–null mice but not in companion 
wild-type mice compared with their respective 
controls (Figure 2). In the David et al. study of 
B6C3F1 mice, DEHP (500 ppm) also signifi-
cantly increased adenomas and adenomas plus 
carcinomas (Figure 2). Moreover, we found a 
significant dose–response trend for adenomas 
and for adenomas plus carcinomas in both the 
Ito et al. PPAR-α–null mice and the David 
et al. B6C3F1 mice after exposure to DEHP 
(Figure 2). Additionally, we found no statisti-
cally significant differences between groups at 
the same dose, including controls, consistent 
with mouse strain and PPAR-α genotype hav-
ing no influence on carcinogenicity under the 
study conditions.
The observed lack of difference in reported 
control incidences across groups lends sup-
port to our approach of basing comparative 
analyses on concurrent controls. Historical 
data on spontaneous liver tumor incidences 
in PPAR-α–null mice are limited; Ito et al. 
(2007a) is the largest published 2-year bio-
assay in PPAR-α–null mice, reporting find-
ings for 24 of 25 surviving unexposed animals 
at 23 months of age. A different laboratory 
that had established a distinct breeding colony 
reported mouse liver tumor incidences in 12 
PPAR-α–null Sv129/C57BL/6 mice approxi-
mately 2 years of age (Howroyd et al. 2004). 
Adenomas and carcinomas were reported 
in 6 of 12 and 2 of 12 PPAR-α–null mice, 
respectively, compared with adenomas in 5 of 
22 wild-type animals. As Howroyd et al. noted, 
“The relatively small number of animals avail-
able made it difficult to draw robust conclu-
sions concerning enhancement of spontaneous 
findings in PPARα-null mice.” In addition, the 
low survival of Howroyd et al.’s PPAR-α–null 
mice relative to those of Ito et al. (2007a) limit 
statistical comparisons based on this data set.
In sum, the Ito et al. (2007a) study is 
consistent with the view that DEHP carcino-
genesis can occur independently of PPAR-α 
activation. As noted in a report by the National 
Research Council (2008a), this finding “calls 
into question” the IARC conclu  sions regarding 
the carcinogenic risks of DEHP (IARC 2000). 
Indeed, as summarized in Figure 1B, PPAR-α 
activation and the subsequent key events in 
the hypothesized MOA do not appear to rep-
resent the sole cause of DEHP liver tumori-
genesis. Although new hypotheses are being 
generated based on more detailed comparisons 
between wild-type and PPAR-α–null mice 
(Ito et al. 2007a; Takashima et al. 2008), the 
mechanisms by which DEHP induces hepato-
carcinogenesis remain unknown.
Do PPAR-α Activation and 
Its Sequelae in Hepatocytes 
Cause Cancer?
A second recent study raises further   questions 
regarding whether PPAR-α activation in 
hepato  cytes is causally linked to hepatocarcino-
genesis as a sole operant MOA (Yang et al. 
2007). The experimental approach entailed 
fusing the mouse PPAR-α to the potent viral 
transcriptional activator VP16 under control of 
the liver-enriched activator protein (LAP) pro-
moter, resulting in targeted constitutive expres-
sion of activated PPAR-α in hepatocytes. In 
LAP-VP16PPAR-α transgenic mice, many of 
the same hepatic responses (in type and mag-
nitude) were seen as with PPAR-α ligand treat-
ment of companion wild-type Sv129 mice. For 
instance, DNA synthesis was increased in LAP-
VP16PPAR-α transgenic mice; the effect was 
persistent and still evident at 11 months of age. 
In addition, increases were reported in markers 
of peroxisome proliferation [including increases 
in expression of peroxisomal membrane pro-
tein 70, acyl coenzyme A (CoA) oxidase and 
cytochrome P4A (CYP4A) family genes, and 
enhanced cyanide-insensitive palmitoyl CoA 
oxidation]. Other effects included an increase 
in cell-cycle genes (cyclin D1 and cyclin- 
dependent kinase-1 and -4) and a decrease 
in serum triglycerides and free fatty acids. 
Together, the results from this transgenic 
model are consistent with the view that 
PPAR-α activation and its sequelae are alone 
sufficient to induce increased hepatocyte DNA 
synthesis (a key event in the hypothesized 
MOA) as well as peroxisome proliferation.
However, constitutive PPAR-α activation 
in hepatocytes in the LAP-VP16PPAR-α trans-
genic mouse model was not sufficient to induce 
several important hepatic responses stimu-
lated by PPAR-α ligand treatment of wild-
type mice. Notably, Yang et al. (2007) found 
no preneoplastic hepatic lesions or hepato-
cellular neoplasia in “> 20 LAP-VP16PPAR-α 
mice at the age of < 1 year.” In sharp con-
trast, wild-type mice exposed to the PPAR-α 
agonist Wy-14,643 for 11 months developed 
grossly visible lesions consistent with previous 
reports of its hepatocarcinogenicity (e.g., Peters 
et al. 1997). Interestingly, nonparenchymal 
cell proliferation was seen with Wy-14,643 
exposure of wild-type mice but was absent in 
the LAP-VP16PPAR-α transgenic mice. In 
addition, although liver weight was increased 
in LAP-VP16PPAR-α transgenic mice, the 
extent of hepatomegaly was reduced compared 
with Wy-14,643–exposed wild-type mice, and 
hepatocellular hypertrophy was absent.
Figure 2. Incidences of hepatocellular adenomas (A) and hepatocellular adenomas and carcinomas (B) 
in mice exposed to DEHP. Ito et al. (2007a) exposed PPAR-α–null (–/–) and wild-type (+/+) Sv129 mice for 
22 months; David et al. (1999) exposed B6C3F1 wild-type (+/+) mice for up to 104 weeks. Data are presented 
as incidence ± SD assuming a binomial distribution for each group. All pairwise cross-study comparisons 
between like dose groups [e.g., Ito et al. 2007a (–/–) 500 ppm vs. David et al. (+/+) 500 ppm] were not sig-
nificant by Fisher exact test. Because David et al. reported only adenomas and carcinomas, we excluded 
from analyses the cholangiocellular carcinoma reported by Ito et al. in DEHP-exposed PPAR-α–null mice.
*Significantly different from controls of the same genotype in the same study (Fisher exact test, p < 0.05). **Significant 
trend with dose in the study (Cochran Armitage test, p < 0.05).
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Thus, the Yang et al. (2007) study pro-
vides evidence that, by itself, PPAR-α acti-
vation (and its sequelae) is not sufficient to 
induce hepatocarcinogenesis. These data are 
therefore inconsistent with the hypothesis 
that effects mediated through PPAR-α activa-
tion constitute a complete MOA for carcino-
genesis (Figure 1C). Notably, key events in 
the proposed MOA such as the robust and 
sustained elevation in hepatocyte prolifera-
tion (evidenced by enhanced DNA synthesis), 
accompanied by enzyme changes commonly 
associated with peroxisome proliferation, 
did not evoke hepatocarcinogenesis. In fact, 
a comparable extent of sustained increases 
in hepatocyte DNA synthesis was seen with 
constitutive PPAR-α activation in the LAP-
VP16PPAR-α transgenic mouse model and 
Wy-14,643 exposure in wild-type mice, but 
only the latter developed liver tumors under 
comparable experimental paradigms.
These observations indicate that events 
besides the prolonged elevation of proli  feration 
(evidenced by an increase in DNA synthesis) 
are necessary in the carcinogenic MOA for 
Wy-14,643, a compound frequently used as 
the model for PPAR-α agonism. Moreover, in 
contrast to Wy-14,643, DEHP only transiently 
increases DNA synthesis and at higher doses 
than required for carcinogenesis (Conway 
et al. 1989; David et al. 1999; Marsman et al. 
1988) (Table 1). Only short-term increases in 
rat liver DNA synthesis are seen with many 
other PPAR-α agonists, including clofibrate 
[ethyl 2-(4-chlorophenoxy)-2-methylpro-
panoate] (Tanaka et al. 1992), clofibric acid 
[2-(p-chlorophenoxy)-2-methylpropionic acid] 
(Barrass et al. 1993; Marsman et al. 1992), 
nafenopin (2-methyl-2[p-(1,2,3,4-tetrahydro-
1-naphthyl)phenoxy]-propionic acid) (Eacho 
et al. 1991; Lake et al. 1993), ciprofibrate 
(2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-
methylpropanoic acid) (Yeldandi et al. 1989), 
and trichloroacetic acid (TCA) (Walgren et al. 
2005). A causal mechanistic link between tran-
sient increases in DNA synthesis and rodent 
hepatocarcinogenesis remains to be established 
(Melnick et al. 1993).
Are key or associative events in the PPAR-α 
activation MOA quantitatively predictive of 
hepatocarcinogenicity? Another question to 
consider is whether potency for PPAR-α acti-
vation or its attendant sequelae is quantita-
tively associated with carcinogenic activity or 
potency. If so, differences in sensitivity for car-
cinogenesis (such as may occur across species) 
could be predicted using quantitative infor-
mation about the key events alone. However, 
there are limitations in the dose–response data 
available for analyses of quantitative relation-
ships between potencies for precursor events 
in the proposed PPAR-α activation MOA and 
for liver tumor induction. Most tumor data, 
including for the best-characterized PPAR-α 
agonists, are for exposure concentrations 
inducing well above 50% carcinogenic potency 
(TD50; the daily dose inducing tumors in 
half of the mice that would otherwise have 
remained tumor-free) with less-than-lifetime 
administration. Precursor events have typi-
cally been studied at a single dose, often elicit-
ing a near maximal response, thus precluding 
benchmark-based comparisons across studies. 
This is especially true for Wy-14,643, which 
has been administered most often at only one 
exposure concentration (1,000 ppm) that elic-
its a 100% tumor incidence after 1 year or less 
(Peters et al. 1997) and that also appears to be 
necrogenic (Woods et al. 2007). On the other 
hand, hypothesized precursor events such 
as hepatomegaly, peroxi  some proliferation, 
and increased DNA synthesis appear to have 
reached their maximal responses at 50 ppm 
Wy-14,643, with some statistically significant 
responses at doses as low as 5 ppm (Marsman 
et al. 1992; Wada et al. 1992). Potencies 
across compounds have rarely been compared 
in a single study using the same experimen-
tal paradigm. These deficits in the database 
notwithstanding, we provide below an assess-
ment of the quantitative predictive power of 
the potency for four proposed data elements 
for establishing the hypothesized MOA for 
hepatocarcinogenesis: PPAR-α activation in 
mice, and hepato  megaly, DNA synthesis, and 
increased peroxisome proliferation in rats.
PPAR-α activation in mice. Table 2 pres-
ents data for four peroxisome proliferators in 
order of decreasing potency for inducing mouse 
liver tumors. We selected these compounds 
because of their importance to environmental 
human health risk assessments and because 
data to derive receptor activation potency 
indicators were available from a single study 
(Maloney and Waxman 1999). The trans-
activation potencies of MEHP, Wy-14,643, 
dichloroacetic acid (DCA), and TCA for 
the mouse PPAR-α were monitored using a 
luciferase reporter gene containing multiple 
PPAR response elements derived from the rat 
hydratase/dehydrogenase promoter in tran-
siently transfected COS-1 monkey kidney cells. 
The derived potency indicators were compared 
with the TD50 from the Carcinogenic Potency 
Database (CPDB) of Gold et al. (2005). Note 
that for Wy-14,643, the dose listed yielded a 
maximal response and thus represents an upper 
limit to the TD50 (indicated by “<“). Two esti-
mates of PPAR-α transactivation potency are 
given, the first based on the effective concen-
tration yielding 50% of the maximal response 
(EC50) and the second based on the effective 
concentration required for a 2-fold increase 
in activity (EC2-fold) (Maloney and Waxman 
1999). Orally administered DEHP under-
goes pre  systemic hydrolysis catalyzed by lipase 
to MEHP in the gut, with mice exhibiting 
higher lipase activities in the small intestine 
compared with rats and marmosets (Ito et al. 
2005; Kessler et al. 2004; Pollack et al. 1985). 
Therefore, because the mouse liver is likely 
exposed predominantly to MEHP rather than 
DEHP and because unmetabolized DEHP 
does not exhibit PPAR-α activity, the transacti-
vation activity of its metabolite MEHP is given 
but compared with the hepatocarcinogenic 
potency indicator for DEHP. No data on the 
potency for transactivation of rat PPAR-α by 
chemicals in the CPDB were located to enable 
a similar comparison in rats.
These data clearly show a lack of correla-
tion between the potencies for in vitro PPAR-α 
transactivation and in vivo tumori  genesis 
across different PPAR-α agonists. Especially 
notable is that MEHP exhibited orders of 
Table 2. Potency indicators for mouse hepato-
carcinogenicity and in vitro transactivation of 
mouse PPAR-α for four PPAR-α agonists. 
Hepatocarcinogen
Carcinogenic 
potency indicator 
(TD50; mg/kg-day)
Transactivation 
potency  
indicators (μM)
EC50 EC2-fold
Wy-14,643 < 10.8 0.63 ~0.4
DCA 119.0 ~800 ~600
TCA 584.0 ~500 ~300
DEHP/MEHP 700.0 ~0.7 ~0.7
The “<“ symbol denotes an upper limit due to maximal 
response. A “~” symbol indicates that the trans  activation 
potency was approximated (to one significant figure) 
from figures or tables in Maloney and Waxman (1999).
Table 1. Potency indicators for rat hepatocarcinogenicity and common short-term markers of PPAR-α 
activation for four PPAR-α agonists. 
Chemical
Tumor TD50 
(ppm in diet)
Fold increase over control at tumor TD50
1 week 13 weeks
RLW LI PCO RLW LI PCO
Wy-14,643 109 1.8 12.0 13.0 2.6 6.8 39.0
Nafenopin 275 1.4 3.6 7.6 1.5 1.12 6.7
Clofibrate 4,225 1.4 4.4 4.2 1.4 0.95 3.7
DEHP 17,900 ≥ 1.4 ≥ 19.0 ≥ 3.6 ≥ 1.9 ≥ 1.25 ≥ 4.9
Abbreviations: LI, labeling index; PCO, cyanide-insensitive palmitoyl CoA oxidation; RLW, relative liver weight; TD50, daily 
dose inducing tumors in half of the mice that would otherwise have remained tumor-free. For ease of comparison with 
precursor effect studies, administered doses for the tumor TD50 values in the CPDB were back-converted to equivalent 
parts per million in diet using the formula of Gold et al. (2005): TD50 (mg/kg-day) = TD50 (ppm in diet) × 0.04 (for male rats). 
Administered doses for precursor data on Wy-14,643 (Wada et al. 1992) and clofibrate (Tanaka et al. 1992) were within 
10% of the TD50. Because nafenopin precursor data were available only at 0 and 500 ppm (Lake et al. 1993), these doses 
were linearly interpolated to the TD50. Because the highest administered dose of DEHP in precursor effect studies was 
12,500 ppm (David et al. 1999), a lower limit is shown, based on the assumption of monotonicity with dose.Guyton et al.
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magnitude more potency for transactivating 
mouse PPAR-α than does DCA, but DEHP 
was 6-fold less potent as a mouse hepatocar-
cinogen. TCA was more similar in potency to 
DCA for both outcomes; that is, it was also dra-
matically less active at transactivating PPAR-α 
than DEHP despite exhibiting comparable 
hepatocarcinogenic potency. Wy-14,643 and 
MEHP activate PPAR-α at comparable con-
centrations when directly compared in the 
trans  activation assay, but the carcinogenic 
potency of Wy-14,643 was estimated to be at 
least 70-fold higher than that of DEHP. This 
difference cannot be explained by hepatic con-
version of DEHP to its monoester MEHP, 
because studies in rats demonstrate that orally 
adminis  tered DEHP undergoes presystemic 
hydrolysis to MEHP in the gut (Kessler et al. 
2004; Pollack et al. 1985). Possible explanations 
for these results include one or more of the fol-
lowing: a) the transactivation assay may not 
be an accurate quantitative indicator of in vivo 
receptor activation; b) the rate and nature of 
effects downstream of PPAR-α activation may 
depend on the ligand; or c) rate-limiting events 
independent of PPAR-α activation may con-
tribute to mouse hepatocarcinogenesis by the 
agonists examined.
Hepatomegaly, DNA synthesis, and peroxi-
some proliferation in rats. Table 1 compares 
potency indicators for various precursor effects 
at the TD50 for four PPAR-α agonists and rat   
hepatocarcinogens. Our analysis of whether 
there are consistent levels of in vivo pre-
cursor effect induction across peroxisome 
proliferators at the TD50 does not include 
all of the data from a similar, prior analysis 
by Ashby et al. (1994), for several reasons. 
First, unlike the CPDB, Ashby et al. did not 
adjust carcino  genicity data for less-than-
lifetime dosing, which is relevant for most 
compounds. Second, for those mouse car-
cinogens reported in the CPDB, only acute 
data are available regarding DNA synthesis 
effects from Ashby et al. (1994). Therefore, 
our analysis was restricted to rat precursor 
and potency data for the four compounds 
Wy-14,643, nafenopin, clofibrate, and DEHP 
and included both 1-week and 13-week data 
to separately address transient and sustained 
changes in DNA synthesis. Even for this 
small set of compounds, several limitations 
in the rat database were apparent. Because 
no single study provided comparative data 
for the precursor end points of interest, we 
used four separate reports. In the Wada et al. 
(1992) and Tanaka et al. (1992) studies 
of Wy-14,643 and clofibrate, respectively, 
administered doses were within 10% of the 
TD50. However, nafenopin data were avail-
able only at a single dose of 500 ppm (Lake 
et al. 1993), which we linearly interpolated to 
the TD50. The highest administered dose of 
DEHP was 12,500 ppm (David et al. 1999), 
a dose notably less than the TD50, and thus a 
lower limit based on the assumption of mono-
tonicity with dose is shown. A further data 
limitation is that in the CPDB, the TD50 
for only one of the four compounds, DEHP, 
incorporates data from studies administering 
more than one dose for 2 years.
The results shown in Table 1 indicate 
that potency for the occurrence of short-term 
in vivo markers of PPAR-α activation varies 
widely in magnitude and lacks any apparent 
correlation with carcinogenic potency. Such 
differences have been noted previously. Similar 
to the results presented in Table 1, Marsman 
et al. (1988) noted that although DEHP 
(12,000 ppm) and Wy-14,643 (1,000 ppm) 
induced a similar extent of hepatomegaly 
and peroxisome proliferation (measured 
either morphologically or biochemically) 
after 1 year, the frequency of hepatocelluar 
lesions was > 100-fold higher in Wy-14,643–
exposed relative to DEHP-exposed rats. In 
addition, a higher labeling index was reported 
for 12,500 ppm DEHP than the maximal 
level attained after 50–1,000 ppm Wy-14,643 
(David et al. 1999; Tanaka et al. 1992; Wada 
et al. 1992). We did not examine such differ-
ences in maximal responses in our analysis. 
We also do not present differences in response 
with dose and time seen among PPAR-α ago-
nists, which are prominent enough to prevent 
displaying dose–response data on a common 
scale. For instance, labeling index, which is a 
measure of DNA synthesis, is increased in a 
dose-dependent manner at 1 week by clofi-
brate (1,500, 4,500, and 9,000 ppm) but is 
decreased compared with controls at 13 weeks 
at the two higher doses (Tanaka et al. 1992). 
Together, these findings underscore the sig-
nificant chemical-specific quantitative differ-
ences in these markers that limit their utility 
for predicting carcinogenic dose–response 
relation  ships.
To What Extent Are Humans 
Sensitive to PPAR-α Agonists?
Toxicodynamic differences across species, 
including in the absolute or allometrically 
scaled amount or activity of the receptor, 
may contribute to differences in sensitivity of 
response to PPAR-α agonists. Absolute lev-
els of PPAR-α are generally thought to be 
lower in human compared with rodent liver. 
However, PPAR-α amount varies by an order 
of magnitude among individuals (Palmer 
et al. 1998; Tugwood et al. 1996); for exam-
ple, one of the six human samples examined 
expressed levels comparable to the mouse in 
one study (Walgren et al. 2000). The pattern 
of PPAR-α expression across tissues also differs 
across species (Melnick 2001; Tugwood et al. 
1996); for example, human levels are higher 
in kidney and skeletal muscle than in liver, 
whereas the highest rodent levels are in liver 
and kidney. In addition, considerable inter-
individual variation in PPAR-α structure and 
function among humans has been reported 
(Tugwood et al. 1996), and polymorphisms 
have been shown to increase or decrease recep-
tor levels and to modu  late baseline lipid and 
apo  lipoprotein levels, athero  sclerotic progres-
sion, and the presence of diabetes mellitus and 
insulin resistance (Flavell et al. 2002, 2005; 
Foucher et al. 2004; Jamshidi et al. 2002; Tai 
et al. 2006; Tanaka et al. 2007). An impact of 
PPAR-α polymorphisms on pre  existing disease 
status and response to PPAR-α agonists is also 
suggested from bezafibrate [2-(4-{2-[(4-chlo-
rophenyl)formamido]ethyl}phenoxy)-2-
methylpropanoic acid] and gem  fibrozil 
[5-(2,5-dimethylphenoxy)-2,2-dimethyl- 
pentanoic acid] trials (Jamshidi et al. 2002; Tai 
et al. 2006).
The human PPAR-α is functional in 
in vitro transactivation assays and is respon-
sive to a number of PPAR-α agonists (e.g., 
nafenopin, clofibrate, and WY-14,643) 
(Maloney and Waxman 1999; Mukherjee 
et al. 1994; Sher et al. 1993). Compared with 
the mouse PPAR-α, human PPAR-α is sug-
gested to be 10- to 20-fold less responsive to 
Wy-14,643 (Maloney and Waxman 1999; 
Mukherjee et al. 1994; Palmer et al. 1998). 
However, this magnitude of inter  species differ-
ence has not been demonstrated for other com-
pounds. Hurst and Waxman (2003) reported a 
5-fold lower sensitivity to the DEHP metabo-
lite MEHP of human compared with mouse 
PPAR-α (EC50 = 3.2 µM vs. 0.6 µM) in 
transfected COS-1 monkey kidney cells, but 
acknowledged that they could not quantify 
the relative amount of each receptor. Using 
a similar experimental paradigm, Wolf et al. 
(2008) found an approximately 2-fold lower 
slope of the dose–response curve for activation 
of human compared with mouse PPAR-α for 
perfluorooctanoic acid and other perfluoro-
alkyl acids. For other compounds that acti-
vate PPAR-α, including TCA and DCA, little 
(< 2-fold) or no species difference in receptor 
transactivation sensitivity was evident (Maloney 
and Waxman 1999). Some compounds appear 
to more efficiently activate human compared 
with rodent PPAR-α in vitro, as was demon-
strated for the synthetic poly  unsaturated 
fatty acid 5,8,11,14-eicosatetraynoic acid in 
transfected human liver cancer HepG2 cells 
(Mukherjee et al. 1994) and for perfluoro-
butane sulfonate in transfected COS-1 monkey 
kidney cells (Wolf et al. 2008).
Using adenovirus expression in PPAR-
α–null mice, Yu et al. (2001) also found little 
(< 2 fold) or no difference between the mouse 
and human receptor in terms of induction 
of in vivo markers of peroxisome prolifera-
tion. Wy-14,643, ciprofibrate, DEHP, and 
nafenopin enhanced mRNA and protein levels 
of peroxisomal genes regardless of whether the The PPAR-α activation MOA hypothesis revisited
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human or mouse PPAR-α was expressed (Yu 
et al. 2001). Transgenic mice stably express-
ing human PPAR-α in the liver only (Cheung 
et al. 2004; Morimura et al. 2006) or in all 
tissues (Yang et al. 2008) of PPAR-α–null 
mice exhibit increases in both DNA synthesis 
(with Wy-14,643) and hepatomegaly (with 
Wy-14,643 and fenofibrate [propan-2-yl 
2-{4-[(4-chlorophenyl)carbonyl]phenoxy}-2-
methylpropanoate]). However, these increases 
were much diminished from the response 
in wild-type mice and lacked statistical sig-
nificance due largely to the small number of 
animals studied (n = 5–9). With regard to 
mouse liver tumor induction, Wy-14,643 
(1,000 ppm) exposure for up to 44 weeks 
induced one liver adenoma in 20 PPAR-α-
humanized mice, whereas none were seen in 
10 untreated animals (Morimura et al. 2006); 
in comparison, Wy-14,643 (1,000 ppm) 
caused lethality in 5 of 10 wild-type mice 
at 38 weeks and tumors in the five surviv-
ing animals. These findings are suggestive of 
differential sensitivity of humanized mice to 
Wy-14,643. However, the accuracy of esti-
mates of the extent of this difference is limited 
by the short exposure duration, the substantial 
mortality and morbidity in wild-type mice, the 
small number of animals studied, and poten-
tial differences in the interaction of the human 
receptor with mouse-specific coactivators and 
response elements.
Several key or associative events in the 
hypothesized MOA have been observed 
directly in some but not all primate studies 
(Hoivik et al. 2004; Ito et al. 2007b; Kurata 
et al. 1998). Studies of cultured primary 
human hepatocytes have generally reported 
little or no proliferative response to perox-
isome proliferators (for reviews, see Ashby 
et al. 1994; Peters et al. 2005; Rusyn et al. 
2006). The culture conditions, including lack 
of cocultured nonparenchymal cells (e.g., 
Kupffer cells), may limit the in vitro hepa-
tocyte proliferative response, as observed for 
other species (e.g., Parzefall et al. 2001). The 
extent of peroxisome proliferation in human 
liver after exposure to fibrate drugs (e.g., 
with clofibrate, gemfibrozil, or fenofibrate) 
or dialysis treatment (possibly due to DEHP 
exposure) is reported to be generally less than 
the rodent response (Blumcke et al. 1983; De 
La Iglesia et al. 1982; Ganning et al. 1984, 
1987; Gariot et al. 1987; Hanefeld et al. 
1980, 1983). However, the ability to quanti-
tatively characterize human sensitivity to this 
effect is limited (e.g., by the small number of 
subjects studied).
In sum, despite notable qualitative simi-
larities, quantitative differences in receptor 
activation and the subsequent events in the 
hypothesized MOA are evident across species. 
The magnitude of these differences has been 
best characterized for Wy-14,643, to which 
rodents appear to have ≥ 10-fold greater sen-
sitivity for response (Cheung et al. 2004; 
Maloney and Waxman 1999; Morimura et al. 
2006; Mukherjee et al. 1994; Palmer et al. 
1998; Yu et al. 2001). Although more lim-
ited, studies of other compounds that activate 
PPAR-α suggest a smaller magnitude of dif-
ference in sensitivity for response across spe-
cies than is seen for Wy-14,643 (Hurst and 
Waxman 2003; Maloney and Waxman 1999; 
Yu et al. 2001). Considerable inter  individual 
variation in PPAR-α amount, structure, and 
function has been reported among humans 
(Tugwood et al. 1996), and some studies 
have suggested variability in human response 
to PPAR-α agonists (Jamshidi et al. 2002; 
Tai et al. 2006). However, few studies have 
directly examined how these factors may affect 
sensitivity—as well as the potential for hetero-
geneity of response—to hepatocarcinogenesis 
induced by PPAR-α agonists in humans.
Do Human Epidemiologic Data 
on Fibrates Offer an Indirect 
Test of the PPAR-α Activation 
MOA Hypothesis?
Human exposures to exogenous and endoge-
nous PPAR-α agonists encompass a broad 
group of chemicals, including environmental 
contaminants known to activate the recep-
tor, as well as a number of therapeutic agents 
whose molecular target is one or more recep-
tors in the PPAR family. Indeed, fibrate drugs 
were developed using rodent models to treat 
hyperlipidemia in humans before the recep-
tor was identified. These agents have vary-
ing degrees of affinity for PPAR-α (Shearer 
and Hoekstra 2003), and some have mul-
tiple mechanisms of action. Drugs that have 
PPAR-α agonist activity include fibrates or 
fibric acid derivatives (which are primarily 
PPAR-α agonists), bezafibrate (which also 
shows PPAR-γ activity), dual PPAR-α/γ 
agonists currently under development, the 
glita  zones, and nonsteriod anti-inflammatory 
drugs (e.g., ibuprofen) (Sertznig et al. 2007).
Some human data on PPAR-α agonist 
effects are available from fibrate clinical trials 
and population case–control studies of site- 
specific cancer (Bezafibrate Infarction Prevention 
Study Group 1992, 2000; Canner et al. 
1986; Committee of Principal Investigators 
1978, 1980, 1984; Coronary Drug Research 
Group 1975, 1977; De Faire et al. 1995; 
Diabetes Atherosclerosis Intervention Study 
Investigators 2001; Freeman et al. 2006;   
Frick et al. 1987, 1997; Huttunen et al. 1994; 
Keech et al. 2005, 2006; Meade 2001; Rubins 
et al. 1993, 1999; Tenkanen et al. 2006). 
These studies examined a range of human 
responses to PPAR-α agonists, which included 
athero  sclerosis, cardio  vascular disease, serum 
bio  markers of fatty acid metabolism, acute 
toxicity, and, more limitedly, organ-specific 
chronic toxicity, including cancer. However, 
examination of hepato  toxicity in the fibrate 
clinical trials has been limited to alterations 
in hepatic metabolic pathways and changes in 
liver enzymes as assessments of drug tolerance, 
because the primary focus of these trials was 
cardiovascular events.
Past reviews of the PPAR-α activation 
MOA hypothesis have generally focused on 
liver cancer response in two fibrate clinical 
trials, the Helsinki Heart Study (Frick et al. 
1987; Huttunen et al. 1994; Tenkanen et al. 
2006) and the World Health Organization’s 
Cooperative Trial on Primary Prevention 
of Ischemic Heart Disease (Committee of 
Principal Investigators 1978, 1980, 1984), 
and have concluded that, although limited, 
those data did not provide evidence of an 
increased liver cancer risk from fibrate expo-
sure (Ashby et al. 1994; Klaunig et al. 2003). 
However, the available studies have low power 
to detect statistical differences in the risk of 
liver cancer; an estimated five or fewer liver 
cancer deaths would have been expected in 
these studies using data from the National 
Cancer Institute’s Surveillance, Epidemiology, 
and End Results database (Ries et al. 2008). 
This low statistical power, in addition to 
the studies’ exclusion or removal of subjects 
showing signs of liver (or other) toxicity from 
treatment, precludes a strong conclusion 
about the presence or lack of liver cancer risk. 
These studies and the other fibrate trials did 
not examine site-specific causes of mortal-
ity or morbidity and did not follow subjects 
for a sufficient period to adequately consider 
cancer latency; in addition, placebo subjects 
were offered fibrate therapy at the end of the 
clinical trials, making analyses after further 
follow-up difficult to interpret. For example, 
the three trials that did assess mortality after 
a follow-up period > 10 years included liver 
cancers in a larger category of contiguous sites 
or in the category of all cancers, introducing 
disease misclassification and a downward bias 
for any site-specific treatment-related cancers 
(Canner et al. 1986; Committee of Principal 
Investigators 1978, 1980, 1984; Huttunen 
et al. 1994; Tenkanen et al. 2006). In vol-
untary postmarketing safety reports to the 
U.S. Food and Drug Administration (FDA), 
rates of liver adverse event reports for gem-
fibrozil and fenofibrate (2.6 and 6.9 per 
1,000,000 prescriptions, respectively) were 
similar to those of statins (Holoshitz et al. 
2008). However, an examination of liver can-
cer is precluded by the general under  reporting 
of chronic toxicities to FDA, and the lack 
of specific FDA reporting requirements for 
cancer, even premarketing. Because of these 
inadequacies, the available epidemiologic data 
for fibrate drugs cannot inform conclusions 
about the relevance of PPAR-α activation to 
human cancer.Guyton et al.
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Conclusions
As summarized in Figure 1D, the data 
reviewed and analyses presented in this 
article raise questions about whether the 
hypothesized PPAR-α activation MOA 
is either necessary or sufficient for rodent 
hepatocarcinogenesis. PPAR-α activation 
clearly plays a significant role in mouse liver 
tumor induction by some agonists, such as 
Wy-14,643. However, the recent study by 
Ito et al. (2007a) suggests that DEHP can 
induce PPAR-α–independent tumors with-
out any loss of potency. In addition, as 
demonstrated by Yang et al. (2007) in their 
transgenic model of PPAR-α activation in 
hepatocytes, a robust hepatocyte and peroxi-
some prolifera  tive response is itself insuffi-
cient to cause tumorigenesis. Despite their 
potential limitations, these studies cast doubt 
on whether the proposed “key events” such 
as hepatocyte proliferation play a causal role 
in tumorigenesis or are merely correlated with 
cancer, as has been suggested for peroxisome 
proliferation in prior reviews (e.g., Klaunig 
et al. 2003). The limited database of other 
studies that empirically challenge the necessity 
or sufficiency of the PPAR-α activation MOA 
in hepatocarcinogenesis per se also motivates a 
reexamination of whether this MOA hypothe-
sis should be used as the basis for dismissing 
the human relevance of effects observed in 
laboratory animals. Of particular concern is 
whether human health risk assessment MOA 
conclusions should be based exclusively on 
evidence of PPAR-α activation and other key 
events in the hypothesized PPAR-α activation 
MOA, given that other modes, mechanisms, 
toxicity pathways and molecular targets may 
contribute to or be required for the observed 
adverse effects. Indeed, for most PPAR-α 
agonists, chemical-specific data to define the 
range of effects that may contribute to human 
carcinogenesis are insufficient. Similarly, the 
epidemiologic data are inadequate to inform 
conclusions of human relevance.
One possibility that deserves further con-
sideration is that the main determinants of 
carcinogenicity may not be captured in the 
hypothesized PPAR-α activation MOA. A 
recent review (Rusyn et al. 2006) addressed 
other mechanistic effects of DEHP and pro-
posed that tumors arise from a combination 
of molecular signals and pathways, rather 
than from a single event such as PPAR-α 
activation. Indeed, the compounds that acti-
vate PPAR-α are pleiotropic and have been 
reported to exhibit a diversity of responses 
in addition to the hallmark effect of peroxi-
some proliferation, including genotoxicity 
(reviewed by Melnick 2001), epigenetic 
alterations (e.g., hypomethylation) (Pogribny 
et al. 2007), oxidative stress (reviewed in 
O’Brien et al. 2005), and effects on other 
receptors (e.g., Guo et al. 2007) and other 
organelles (e.g., mitochondria) within paren-
chymal cells (Lundgren et al. 1987; Scatena 
et al. 2003; Youssef and Badr 1998; Zhou and 
Wallace 1999). Importantly, several of these 
compounds (e.g., Wy-14,643, nafenopin, 
and DEHP) reportedly affect nonparenchy-
mal liver cells that do not express PPAR-α 
(Parzefall et al. 2001; Peters et al. 2000; 
Rose et al. 1997, 1999; Rusyn et al. 2001) as 
well as other organ systems. Not all precur-
sor, toxic, or carcinogenic effects rely solely 
on PPAR-α; for example, in PPAR-α–null 
mice, DEHP causes adverse testicular and 
renal effects at 24 weeks (Ward et al. 1998) 
as well as hepatocarcinogenicity at 2 years 
(Ito et al. 2007a). Indeed, with regard to the 
hepatic, testicular, and pancreatic cancers 
associated with phthalate exposures, a report 
of the National Research Council (2008b) 
concluded that “there is evidence that these 
cancer types may be mediated by mechanisms 
independent of PPARα.” Therefore, the ade-
quacy of the scien  tific basis for the conclusion 
that PPAR-α agonists pose no carcinogenic 
risk to humans requires re  examination.
Perspectives and Future 
Directions
Our exploration of the hypothesized PPAR-α 
activation MOA highlights some of the criti-
cal challenges pertinent to the evaluation 
of mecha  nistic data and its use in decisions 
regarding the relative human sensitivity for 
biological effects observed in laboratory ani-
mals. Primary among these are differentiating 
causative from associative events in a proposed 
MOA, addressing multiple MOA hypotheses, 
and considering how Hill’s considerations 
have been adopted to address these key ques-
tions. Alternatives to the use of Hill’s consid-
erations for assessing causality for toxicologic 
data have been discussed (Gray et al. 2001; 
Guzelian et al. 2005; Weed 2005). In addi-
tion, alternate conceptualizations of causal 
inference that allow for consideration of 
multiple causative factors may be instructive 
for MOA data evaluation. In particular, the 
sufficient-component cause model described 
originally by Rothman (1976) may provide 
useful theoretical and conceptual bases perti-
nent to evaluating MOA data and generating 
new MOA hypotheses. This model facilitates 
the conceptualization of hypotheses regard-
ing multiple causes contributing to a single 
disease of interest and addresses such issues as 
multiple diseases arising from a single cause 
and multiple causes for a single disease with 
distinct models of susceptibility and biologic 
interactions, as well as background risk due 
to endogenous processes or other exposures. 
These “casual inference” methodologies may 
be useful in identifying the candidate key 
events, MOAs, or toxicity pathways that indi-
vidually or together constitute the operant 
MOAs. Thereafter, direct experimentation 
is needed, and thus a critical aspect of MOA 
data evaluation is to consider the extent to 
which hypotheses have been challenged 
experi  mentally, according to the scientific 
method.
With regard to considerations of human 
sensitivity to any given MOA, our analyses 
support a change in focus from using quanti-
tative data to make a “binary” determination 
of “relevant”/“not relevant” during hazard 
identification to a data-driven approach of 
using available quantitative data during dose–
response estimation. This includes incorpo-
rating data-derived estimates of the degree 
of inter- as well as intraspecies differences 
in sensitivity to identified causal events in 
a hypothe  sized MOA during risk evalua-
tion. The extent to which such quantitative 
approaches rely on a single MOA should be 
commensurate with the experimental support 
that the hypothesized MOA is the sole caus-
ative factor for carcinogenesis. These issues 
are especially important if the hypothesized 
MOA would be used as the basis for dismiss-
ing the human relevance of effects observed in 
laboratory   animal models.
These considerations also highlight the 
need for a more robust database for com-
pounds of environmental concern that activate 
PPAR-α, such as phthalates, perfluorinated 
acids, chlorinated solvents, and chloroacetic 
acids, either alone or in combinations relevant 
to human exposures. The extensive research 
focus on Wy-14,643 is particularly problema-
tic, because a) it is typically administered at 
necrogenic doses well above those required for 
maximal responses; b) it is one of the few ago-
nists that produce sustained, as opposed to 
only transient, enhancement of DNA synthesis 
in hepatocytes; c) unlike many other agonists, it 
preferentially activates rodent forms of PPAR-α 
(with humans exhibiting ~20-fold less sensi-
tivity); and d) humans apparently have never 
been exposed to it, either in an experimental 
or clinical setting. Although it is assumed to be 
a prototype for the class, these considerations 
limit the general applicability of the research 
findings with Wy-14,643 to the diverse chemi-
cals that activate PPAR-α. Rather than using 
Wy-14,643 and focusing exclusively on cor-
relative effects in the hypothe  sized PPAR-α 
activation MOA in hepatocytes, experimental 
studies are needed that aim to elucidate and 
characterize the pleiotropic effects of PPAR-α 
agonists. Such research could broadly explore 
other mechanisms and identify the toxic-
ity pathways responsible for effects that are 
known to be associated with human carcino-
genesis. Based on this research, plausible MOA 
hypothe  ses for hepatocarcinogenesis induced 
by these environmental contaminants could 
be generated and ultimately tested using the 
scientific method.The PPAR-α activation MOA hypothesis revisited
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